TEVA - Teva Pharmaceutical Industries Limited
After hours:
| Previous Close | 7.33 |
| Open | 7.45 |
| Bid | 7.45 x 21500 |
| Ask | 7.49 x 4000 |
| Day's Range | 7.33 - 7.50 |
| 52 Week Range | 6.78 - 11.45 |
| Volume | |
| Avg. Volume | 11,968,043 |
| Market Cap | 8.491B |
| Beta (5Y Monthly) | 1.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.46 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Nov 27, 2017 |
| 1y Target Est | 9.72 |
Simply Wall St.Shareholders in Teva Pharmaceutical Industries (NYSE:TEVA) have lost 66%, as stock drops 6.3% this past week
Generally speaking long term investing is the way to go. But no-one is immune from buying too high. For example the...
ZacksZacks Industry Outlook Highlights Amphastar, Dr. Reddy's and Teva Pharmaceutical
Amphastar, Dr. Reddy's and Teva Pharmaceutical have been highlighted in this Industry Outlook article.
Zacks3 Generic Drug Stocks to Watch Amid Macro Headwinds
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.
Business WireTeva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting
TEL AVIV, Israel & PARSIPPANY, N.J., May 20, 2023--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that four studies across its neuroscience portfolio will be presented during the American Psychiatric Association’s (APA) 2023 Annual Meeting taking place on May 20-24, 2023. Abstracts include data for UZEDY (risperidone) extended-release injectable suspension for subcutaneous use, which was recently approved by the FDA for the tr
- Reuters
UPDATE 1-Teva Pharm CEO sees $2.5 bln in revenue for Austedo drug by 2027
Teva Pharmaceutical Industries' drug Austedo should reach sales of $2.5 billion by 2027, Chief Executive Richard Francis said on Thursday. Austedo is Teva's branded treatment for Huntington's Disease but the drug also helps those with movement disorder tardive dyskenisa. Teva expects revenue from Austedo to reach $1.2 billion in 2023 from $971 million in 2022.
Motley FoolWhy Teva Pharmaceutical Stock Is Jumping Today
Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were jumping 5.7% as of 11:21 a.m. ET on Thursday. Francis maintained that focusing on these four areas will enable Teva to "gain momentum as a stronger, bolder, and simpler organization." At least one Wall Street analyst seemed to be convinced that Teva could now be on the right track.
- Reuters
Teva Pharm CEO sees $2.5 bln in revenue for Austedo drug by 2027
Teva Pharmaceutical Industries' drug Austedo should reach sales of $2.5 billion by 2027, chief executive Richard Francis said on Thursday. Austedo is Teva's branded treatment for Huntington's Disease but the drug helps those with the movement disorder tardive dyskenisa. Ahead of unveiling Teva's new strategy, Francis told reporters that only 15% of the 800,000 people suffering from tardive dyskenisa take medication.
- Business Wire
Teva Launches New "Pivot to Growth" Strategy
TEL AVIV, Israel, May 18, 2023--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a new strategic framework with four main pillars to position the Company for a new era of growth. This strategy aims to bolster the Company’s strong commercial portfolio with AUSTEDO®, AJOVY®, UZEDYTM and biosimilars, amplify its innovative pipeline, sustain its generics powerhouse and focus the business. These four pillars are expected to deliver enhanced value and create a greater impact
- Reuters
UPDATE 3-US Supreme Court rejects Teva challenge to $235 million GSK award in patent dispute
The U.S. Supreme Court on Monday declined to hear Teva Pharmaceuticals USA Inc's challenge to a $235 million award to GlaxoSmithKline LLC in a patent dispute over generic drugs involving a heart medication. The justices turned away Israel-based Teva's appeal of a lower court's ruling reinstating the jury award for U.K.-based GSK. The case involves "skinny labels," which allow generic drugmakers to avoid patent lawsuits if a generic drug's label omits potentially infringing uses of a brand-name drug.
ReutersUS Supreme Court rejects Teva challenge to $235 million GSK award in patent dispute
The U.S. Supreme Court on Monday declined to hear Teva Pharmaceuticals USA Inc's challenge to a $235 million award to GlaxoSmithKline LLC in a patent dispute over generic drugs involving a heart medication. The justices turned away Israel-based Teva's appeal of a lower court's ruling reinstating the jury award for U.K.-based GSK. The case involves "skinny labels," which allow generic drugmakers to avoid patent lawsuits if a generic drug's label omits potentially infringing uses of a brand-name drug.
Business WireAUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now Available in the U.S.
TEL AVIV, Israel & PARSIPPANY, N.J., May 15, 2023--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that once-daily AUSTEDO XR (deutetrabenazine) extended-release tablets are now available for adults in the United States in 6 mg, 12 mg and 24 mg tablet strengths. AUSTEDO XR was recently approved by the U.S. Food and Drug Administration (FDA) for adults living with tardive dyskinesia (TD) and chorea associated with Huntington’s d
ZacksTEVA Q1 Earnings Miss Estimates, Sales Beat, Stock Declines
TEVA reports mixed Q1 results, missing earnings estimates but beating the same for revenues. Stock falls.
Motley FoolTeva Pharmaceutical Industries (TEVA) Q1 2023 Earnings Call Transcript
Additional information regarding these statements and our non-GAAP financial measures is available on our earning release and in our SEC Forms 10-K and 10-Q. To begin today's call, Richard Francis, Teva's CEO, will provide an overview of Teva's Q1 2023 results and business performance, recent events, and priorities going forward. Joining Richard and Eli on the call today are Sven Dethlefs, Teva's head of North America business; and Dr. Eric Hughes, our head of R&D and chief medical officer.
ZacksCompared to Estimates, Teva Pharmaceutical Industries Ltd. (TEVA) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Teva Pharmaceutical Industries Ltd. (TEVA) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Business WireTeva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook
TEL AVIV, Israel, May 10, 2023--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2023.
Business WireTeva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding Several ESG Targets Ahead of Schedule
TEL AVIV, Israel, May 09, 2023--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2022 Environmental, Social and Governance (ESG) Progress Report, which highlights the Company's achievements, such as completing more than 40% of its 23 long-term targets, including six ahead of schedule. The Company successfully met its 2030 target to increase energy efficiency, exceeded its 2030 target to reduce total water withdrawal in areas projected to be in water stress and met it
- Thomson Reuters StreetEvents
Q1 2023 Corcept Therapeutics Inc Earnings Call
Q1 2023 Corcept Therapeutics Inc Earnings Call
Business WireU.S. Mental Health Access Program Expands Medicine Donation to Seven New States
SANTA BARBARA, Calif. & PARSIPPANY, N.J., May 03, 2023--Direct Relief, the National Association of Free and Charitable Clinics (NAFC), and Teva Pharmaceuticals, U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced an expansion of medicine donations through their collaborative mental health access program into seven new states to advance access to healthcare for uninsured patients seeking treatment for anxiety and depression.
ZacksEmbecta (EMBC) to Report Q2 Earnings: What's in Store?
Embecta's (EMBC) diabetes care business is expected to have progressed in the fiscal second quarter banking on strong execution of its three strategic pillars.
Business WireTeva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults
PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS, April 29, 2023--Regulatory News: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and MedinCell (Euronext: MEDCL) announced today that the U.S. Food and Drug Administration (FDA) has approved UZEDY (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults. UZEDY is the first subcutaneous, long-acting formulation of risperidone that utilizes SteadyTeq™, a copoly
Business WireTeva to Launch New Growth Strategy at Investor Day
TEL AVIV, Israel, April 27, 2023--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will host an Investor Day on Thursday, May 18, 2023 to launch its new growth strategy and portfolio priorities. The event will take place at the New York Stock Exchange in New York City. Presentations will begin at 12:00 p.m. Eastern Time and are expected to conclude at 2:00 p.m. Eastern Time.
ZacksZimmer Biomet (ZBH) to Report Q1 Earnings: What's in Store?
Zimmer Biomet (ZBH) might have faced an upheaval in business, thanks to the global inflationary situation in terms of mounting labor and raw material costs, severe staffing shortages and supply issues.
Motley Fool1 "Safe" Stock to Avoid and 1 to Consider Buying in April
Many investors have had the unpleasant experience of buying shares of a company they thought was safe, only to see their money evaporate down the line when their investment wasn't as "safe" as their initial impressions. In that vein, one of the hallmarks of safety is reliable and highly recurring revenue and earnings, complete with a durable and defensible profit margin that's consistent over time. Manufacturers of generic pharmaceuticals seem to fit that bill.
Business WireTeva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023
TEL AVIV, Israel, April 14, 2023--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2023 financial results on Wednesday, May 10, 2023 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
ZacksAlvotech (ALVO) Declines on CRL for Humira's Biosimilar Candidate
Alvotech's shares decline as it receives a complete response letter for biosimilar candidate, AVT02, treating autoimmune disorders.
